证券代码：000739 证券简称：普洛药业 公告编号：2024-45 普洛药业股份有限公司 关于下属公司对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 1、近日，普洛药业股份有限公司（以下简称"公司"）下属孙公司 APELOA HONGKONG LIMITED（以下简称"普洛香港"）与 RTW Holding Limited（以下简 称"RTW"）、Bayer HealthCare LLC（以下简称"Bayer"）与 Ji Xing Pharmaceuticals Limited（以下简称"箕星公司"）共同签署了《SECOND AMENDMENT TO SECURITIES SUBSCRIPTION AGREEMENT》（以下简称《证券认购协 议》）。据此，普洛香港投资 2,750,000.36 美元（按照付款日汇率计算约合人 民币 2004.09 万元），以每股 3.3704 美元的价格认购箕星公司 815,927 股 D 轮 优先股，投资完成后占箕星公司 0.58%的股权。 2、根据《深圳证券交易所股票上市规则》、《公司章 ...

证券代码：000739 证券简称：普洛药业 公告编号：2024-44 普洛药业股份有限公司 关于回购公司股份的进展公告 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 时间均符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第9号——回购股份》及公司股份回购方案的相关规定。 1、公司未在下列期间内回购公司股份： （1）自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发生 之日或者在决策过程中，至依法披露之日内； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2024年3月27日召开第九届 董事会第五次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司员工持股计划。 本次回购股份价格不超过人民币20元/股（含），回购资金总额不低于人民币1.5 亿元（含）且不超过人民币3亿元（含）。具体回购股份数量以回购期限届满或 回购股份实施完毕时实际回购股份数量为准。回购期限为自公司董事会审议通过 回购股份方案之日起6个月 ...

[Table_ 相关研究： DocReport] 普洛药业（000739.SZ）:持 2024-03-22 续提升研发能力，进一步提 升运营效率 普洛药业（000739.SZ）:盈 2023-10-22 利能力提升持续兑现，重视 研发与创新发展 [Table_Contacts] [Table_Page] 中报点评|化学制药 证券研究报告 [Table_Title] 普洛药业（000739.SZ） 运营效率提升加研发助力，盈利能力提升 [Table_Summary] 核心观点： ⚫ 原料药制剂一体化优势提升，不断增强企业核心竞争力。根据公司半 年报披露，公司 2024 上半年实现营业收入 64.29 亿元，同比增长 7.96%；实现归母净利润 6.25 亿元，同比增长 3.96%；实现扣非归母 净利润 6.02 亿元，同比增长 1.24%。截止至 2024 上半年末，公司共 有研发人员 1085 名，研发费用 3.15 亿元，两个 API 品种注册获批， 20 个原料药品种新递交国内外 DMF。 ⚫ 制剂业务规模效应带动盈利能力提升显著，CDMO 业务增长稳健。根 据公司半年报披露，2024 上半年，公司原料药 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company reported a revenue of 6.429 billion yuan for H1 2024, representing a year-on-year growth of 7.96%, and a net profit attributable to shareholders of 625 million yuan, up 3.96% year-on-year [2][3] - The raw material drug intermediate business shows signs of recovery, with revenue of 4.704 billion yuan in H1 2024, a year-on-year increase of 11.89% [3] - The CDMO segment's revenue was 1.028 billion yuan in H1 2024, a decrease of 9.82% year-on-year, but the number of projects and clients continues to grow significantly [3] - The formulation business achieved revenue of 680 million yuan in H1 2024, with a year-on-year growth of 18.37% and a gross margin of 60.30%, an increase of nearly 10 percentage points [3] Summary by Sections Financial Performance - For H1 2024, the company achieved a revenue of 6.429 billion yuan, with a quarterly revenue of 3.231 billion yuan in Q2, reflecting a 12.61% year-on-year growth [2][3] - The net profit for H1 2024 was 625 million yuan, with Q2 net profit at 381 million yuan, showing a 5.35% increase year-on-year [2][3] Business Segments - The raw material drug intermediate segment's revenue was 4.704 billion yuan, with a gross margin of 16.22%, a decrease of 2.30 percentage points year-on-year [3] - The CDMO segment reported a revenue of 1.028 billion yuan, with a gross margin of 40.09%, down 4.68 percentage points year-on-year [3] - The formulation segment's revenue was 680 million yuan, with a gross margin of 60.30%, reflecting a significant improvement [3] Future Projections - The company is expected to achieve net profits of 1.191 billion yuan, 1.356 billion yuan, and 1.571 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 12.84%, 13.86%, and 15.88% [4] - The projected PE ratios for 2024, 2025, and 2026 are 15, 13, and 11 times respectively [4]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook based on financial performance and growth projections. Core Insights - The company achieved a revenue of 6.429 billion yuan in H1 2024, representing a year-on-year increase of 7.96%, with a net profit attributable to shareholders of 625 million yuan, up 3.96% year-on-year [1] - The report highlights improvements in gross margin and a decrease in expense ratios, with a gross margin of 24.70% in H1 2024, down 1.90 percentage points year-on-year, and a net profit margin of 9.72%, down 0.37 percentage points year-on-year [1] - The API business is showing steady progress, with revenue from raw material intermediates reaching 4.704 billion yuan in H1 2024, an increase of 11.89% year-on-year, and the company added 15 new clients during the first half of the year [1] - The CDMO business is undergoing transformation, with a reported revenue of 1.028 billion yuan in H1 2024, a decrease of 9.82% year-on-year, but the number of ongoing projects has increased significantly [1] - The formulation business has seen high growth, with revenue of 680 million yuan in H1 2024, up 18.37% year-on-year, and the company has a robust pipeline of products under development [1] Financial Summary - The company is projected to achieve revenues of 12.48 billion yuan, 13.96 billion yuan, and 15.54 billion yuan for the years 2024, 2025, and 2026, respectively, with year-on-year growth rates of 8.8%, 11.9%, and 11.3% [2] - The net profit attributable to shareholders is expected to be 1.234 billion yuan, 1.472 billion yuan, and 1.708 billion yuan for the years 2024, 2025, and 2026, reflecting growth rates of 16.9%, 19.3%, and 16.0% [2] - The gross margin is projected to be 25.2% in 2024, with a gradual increase to 25.9% by 2026 [3] - The company’s P/E ratios are forecasted to be 14.1, 11.9, and 10.2 for the years 2024, 2025, and 2026, indicating a potentially attractive valuation [2][3]

总市值（亿）： 181.13 魏赟 执业登记编码：S0760522030005 制剂放量盈利能力快速提升，制剂品种有望快速丰富。2024 年 H1 制剂 业务收入 6.8 亿元（+18.4%），毛利率 60.3%（+9.9pct）。2024 年 H1 在研、 完成验证、申报项目分别 51、9、6 个，减重降糖项目预计 2024 年四季度进 入临床，持续丰富的抗感染类、心脑血管类等制剂带来广阔的增长空间。2024 年 H1，奥司他韦、头孢地尼干混悬剂等 5 个国内制剂递交注册申请；制剂 处于大幅增的阶段，每年新立项 25 个左右。从 2026 年开始每年会有 15-20 个上市，新增制剂持续提供增长动力。头孢固体制剂、国际化高端制剂等车 间增设、建设将保障供应能力。 邮箱：weiyun@sxzq.com 化学原料药 普洛药业（000739.SZ） 买入-B(维持) 业绩符合预期，原料药、制剂、CDMO 项目持续丰富，业绩增长拐点已现 事件描述 2024 年 8 月 20 日 ，业绩加速增长 公司研究/公司快报 公司近一年市场表现 8 月 16 日，公司发布 2024 年半年报，2024 年 H1 公司收入 64 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company reported better-than-expected performance in H1 2024, with revenue and profit showing positive growth despite a high base in Q2. Revenue increased by 7.96% year-on-year to 6.43 billion yuan, while net profit rose by 3.96% to 625 million yuan [2][6] - The company is expected to maintain growth momentum in the second half of 2024 as new production capacity is gradually released and projects are fulfilled [6] Financial Performance Summary - **Revenue and Profit Forecasts**: - 2024 revenue is projected at 12.72 billion yuan, with a growth rate of 10.82%. Net profit is expected to reach 1.14 billion yuan, growing by 7.90% [2][6] - **Key Financial Metrics**: - Revenue for H1 2024 was 6.43 billion yuan, with a gross margin of 24.70%, down 1.90 percentage points year-on-year. The second quarter saw revenue of 3.23 billion yuan, up 12.61% year-on-year [2][6] - The company’s net profit margin for H1 2024 was 9.73%, reflecting a stable performance despite market challenges [6] Business Segment Performance - **API and Intermediate Products**: - Revenue from API intermediates in H1 2024 was 4.70 billion yuan, up 11.89% year-on-year, with a gross margin of 16.22% [18][19] - **Formulations**: - Formulation revenue reached 679 million yuan in H1 2024, growing by 18.47% year-on-year, with a gross margin of 60.30% [20] - **CDMO Services**: - CDMO revenue was 1.03 billion yuan in H1 2024, down 9.82% year-on-year, but project numbers are increasing rapidly, indicating potential for recovery [14][15] Cost and Expense Management - **Cost Structure**: - The overall expense ratio decreased, with selling expenses at 4.36% and management expenses at 3.65% in H1 2024. R&D expenses were 315 million yuan, accounting for 4.90% of revenue [24] - **Gross Margin Improvement**: - The gross margin improved in Q2 2024 to 25.35%, indicating effective cost management strategies [24] Future Outlook - The company is expected to benefit from a rich pipeline of products and ongoing capacity expansion, which should support sustained revenue growth in the coming years [2][6] - The report highlights the company's strong competitive position and resilience in a challenging industry environment, suggesting a favorable outlook for continued performance improvement [6]

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company achieved strong performance in H1 2024, with revenue of 6.429 billion yuan, a year-on-year increase of 7.96%, and a net profit attributable to shareholders of 625 million yuan, up 3.96% year-on-year [2] - The raw material drug segment showed steady growth, with sales revenue of 4.704 billion yuan, a year-on-year increase of 11.89%, although gross profit decreased by 1.99% [2] - The CDMO business saw a significant increase in project numbers, with 731 quoted projects, a 51% year-on-year increase, and 876 ongoing projects, a 44% increase [3] - The formulation segment experienced rapid growth, achieving revenue of 680 million yuan, an 18.37% year-on-year increase, and gross profit of 410 million yuan, a 41.67% increase [3] - The company expects revenue for 2024-2026 to be 12.679 billion, 14.317 billion, and 16.014 billion yuan respectively, with net profits of 1.180 billion, 1.466 billion, and 1.747 billion yuan [3] Summary by Sections Financial Performance - In H1 2024, the company reported a revenue of 6.429 billion yuan and a net profit of 625 million yuan, with Q2 alone achieving a revenue of 3.231 billion yuan, marking a 12.61% increase year-on-year [2] - The gross profit margin for the raw material drug segment was 16.22%, down 2.30 percentage points year-on-year [2] Business Segments - The raw material drug intermediate segment's sales revenue was 4.704 billion yuan, with multiple products achieving record sales [2] - The CDMO segment's revenue was 1.028 billion yuan, with a gross profit margin of 40.09% [3] - The formulation segment's revenue was 680 million yuan, with a gross profit margin of 60.30%, reflecting a significant increase in production capacity and cost control [3] Future Outlook - The company anticipates a steady increase in market share for core antibiotic products and expects new product launches and capacity expansions to contribute to performance [2] - The projected earnings per share (EPS) for 2024-2026 are 1.01, 1.25, and 1.49 yuan, with corresponding price-to-earnings (P/E) ratios of 15.43, 12.42, and 10.42 [3]

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|----------------------------------------------------------------| | 投资者关系活动 | | | | ■其他 （投资者电话交流会） | | 类别 | | | | （孙建、郭双喜、盖文化）浙商证券；（孙媛媛、黄翰漾、翁雨晴） | | | 兴业证券；（邓周宇、魏赟、张智勇）山西证券；（张琎、吴婉桦） | | | 中金公司；（李龙峰、侯彪、许菲菲）招商证券；（韩世通、王郑洋、 | | | 王凯旋）中信医药；（张树声、李雨蓓、祝嘉琦）中泰证券；（乔波 | | | 耀）民生证券；（孙曼萁）华西证券；（张绍辉）华福医药；（胡健 | | | 东）华创证券；（杨馥瑗）华安医药；（阮帅）开源证券；（陈辛、 | | | 李奕玮）华泰证券；（江熠暄、孔维崎）国海医药；（臧文清）平安 | | | 证券；（史慧颖）信达医药；（田鑫）广发医药；（杨天笑）西南医 | | | 药；（彭思宇、沈鹭）国信证券；（陶宸冉）国盛证券； ...

何总副总经理兼董事会秘书周总财务总监张总以及董事会办公室主任兼证券事务代表关总就昨天刚刚发布的2024年公司中报的情况跟大家做沟通和交流然后我先简单介绍一下整个2024年中报我们看到 公司当季度把收入和利润都创了历史的这个单季的新高同时在背后也验证了公司过去几年一直 跟市场传递的从做精油原料做优质剂做强CDMO整个战略的落地无论是我们原料业务过一年的稳定增长还是我们质剂业务环比快速的一个增长这个都让我们看到这句话都在快速兑现同时CDMO的报价项目也呈现了一个非常快速增长我相信这都是过一年公司从能力建设 到公司整个资本开支逐步进入一个兑现期所呈现的一个表现所以我们团队也非常看好公司未来几年持续的这么一个趋势所以也恭喜公司取得这样亮丽的夜景就是今天跟我一起主持的还有我们团队的郭双喜博士以及文化 然后首先我们进入我们今天会议的第一个环节有请普洱药业总经理何总就昨天刚刚发布的中报的情况跟大家做这个简单的一个介绍何总好的各位投资者上午好我是普洱药业何春下面由我对公司上半年的经营情况做个简单的介绍 那么从大环境来看的话上半年整个医药行业的外围环境还是比较严峻的一方面地缘政治影响还在然后行业内卷和国内价格的治理还有医药领域 ...